An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics

Journal of Clinical Pharmacology

Volumn 55, Issue 12, 2015, Pages 1395-1405

  Mendell, Jeanne ^a   Johnson, Lisa ^b   Chen, Shuquan ^a  

^a DAIICHI SANKYO INC   (United States)

^b ALLERGAN PLC   (United States)

Author keywords

aPTT; edoxaban; hepatic impairment; pharmacokinetics; PT; safety

Indexed keywords

BILIRUBIN; DRUG METABOLITE; EDOXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MILD HEPATIC IMPAIRMENT; MODERATE HEPATIC IMPAIRMENT; OPEN STUDY; PARALLEL DESIGN; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL; PROTHROMBIN TIME; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; ADOLESCENT; CLINICAL TRIAL; CONTRAINDICATIONS; LIVER DISEASE; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; FACTOR XA INHIBITORS; FEMALE; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; PYRIDINES; THIAZOLES; YOUNG ADULT;

EID: 84954367009     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.550     Document Type: Article

References (40)

1. Furugohri T, Isobe K, Honda Y, et al., DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008; 6: 1542-1549.
2. Giugliano RP, Ruff CT, Braunwald E, et al., Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369: 2093-2104.
3. The Hokusai VTE Investigators, Buller HR, Decousus H, et al., Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013; 369: 1406-1415.
4. ® (Edoxaban tosilate hydrate tablets). Full prescribing information. Tokyo, Japan: Daiichi Sankyo Company, Ltd. 2014.
5. SAVAYSA™ (edoxaban) tablets for oral use. Full Prescribing Information. Parsippany, NJ: Daiichi Sankyo Inc; 2015.
6. Mendell J, Zahir H, Matsushima N, et al., Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs. 2013; 13: 331-342.
7. Mendell J, Chen S, He L, Desai M, Parasrampuria DA., The Effect of Rifampin on the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Edoxaban in Healthy Subjects. J Thromb Haemost. 2014; 12: Abstract COA26.
8. Bathala MS, Masumoto H, Oguma T, He L, Lowrie C, Mendell J., Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos. 2012; 40: 2250-2255.
9. Matsushima N, Lee F, Sato T, Weiss D, Mendell J., Bioavailability and safety of the factor Xa inhibitor edoxaban and the effects of quinidine in healthy subjects. Clin Phamacol Drug Dev. 2013; 2: 358-366.
10. Salazar DE, Mendell J, Kastrissios H, et al., Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost. 2012; 107: 925-936.
11. Mikkaichi T, Yoshigae Y, Masumoto H, et al., Edoxaban transport via P-glycoprotein is a key factor for the drug's disposition. Drug Metab Dispos. 2014; 42: 520-528.
12. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ., Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285: 2864-2870.
13. Cushman M., Epidemiology and risk factors for venous thrombosis. Semin Hematol. 2007; 44: 62-69.
14. Frith J, Jones D, Newton JL., Chronic liver disease in an ageing population. Age Ageing. 2009; 38: 11-18.
15. Lazo M, Hernaez R, Eberhardt MS, et al., Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988- 1994. Am J Epidemiol. 2013; 178: 38-45.
16. Verbeeck RK., Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008; 64: 1147-1161.
17. Amitrano L, Guardascione MA, Brancaccio V, Balzano A., Coagulation disorders in liver disease. Semin Liver Dis. 2002; 22: 83-96.
18. Plessier A, Denninger MH, Consigny Y, et al., Coagulation disorders in patients with cirrhosis and severe sepsis. Liver Int. 2003; 23: 440-448.
19. US Food and Drug Administration. Guidance for industry. Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072123.pdf. 2003.
20. European Medicines Agency Evaluation of Medicines for Human Use Committee for Medicinal Products for Human Use. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003122.pdf. 2005.
21. Fuji T, Fujita S, Kawai Y, et al., A randomized, open-label trial of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery. Thromb J. 2015; 13: 6.
22. Koretsune Y, Yamashita T, Yasaka M., Evaluation of edoxaban in patients with atrial fibrillation and severe renal impairment Eur Heart J. 2013; 34: Abstract P520.
23. Child CG, Turcotte JG., Surgery and portal hypertension. Major Probl Clin Surg. 1964; 1: 1-85.
24. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R., Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973; 60: 646-649.
25. Cockcroft DW, Gault MH., Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31-41.
26. Betrosian AP, Agarwal B, Douzinas EE., Acute renal dysfunction in liver diseases. World J Gastroenterol. 2007; 13: 5552-5559.
27. Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P., Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol. 2005; 16: 763-773.
28. Levey AS, Coresh J, Greene T, et al., Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006; 145: 247-254.
29. Brater DC., Measurement of renal function during drug development. Br J Clin Pharmacol. 2002; 54: 87-95.
30. Quigley EM., Gastrointestinal dysfunction in liver disease and portal hypertension. Gut-liver interactions revisited. Dig Dis Sci. 1996; 41: 557-561.
31. Thachil J., Relevance of clotting tests in liver disease. Postgrad Med J. 2008; 84: 177-181.
32. Nwokediuko SC, Ibegbulam OG., Platelet function and other indices of hemostasis in chronic liver disease. Gastroenterol Res. 2010; 3: 167-170.
33. Tripodi A, Mannucci PM., The coagulopathy of chronic liver disease. N Engl J Med. 2011; 365: 147-156.
34. Tripodi A, Salerno F, Chantarangkul V, et al., Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology. 2005; 41: 553-558.
35. Stangier J, Stahle H, Rathgen K, Roth W, Shakeri-Nejad K., Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol. 2008; 48: 1411-1419.
36. Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D., Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos. 2009; 37: 1056-1064.
37. Kubitza D, Roth A, Becka M, et al., Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2013; 76: 89-98.
38. ® (rivaroxaban) tablets. Full prescribing information. Titusville, NJ: Janssen Pharmaceutical, Inc; 2011.
39. ® (apixaban) tablets for oral use. Full prescribing information. Princeton, NJ: Bristol-Myers Squibb Company; 2012.
40. US Food and Drug Administration. SAVAYSA (edoxaban) tablets. FDA Draft Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee. NDA 206316. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ucm420703.htm 2014.